Carfilzomib's lead over ixazomib in myeloma drug tests was smaller in marrow with more plasma cells
In lab tests of myeloma medicines, the gap between two drugs often varied with the share of plasma cells in the marrow sample. For example, carfilzomib still led ixazomib at both visits in all 16 people tested twice, but usually by less in the sample with more plasma cells. A smaller lead on a repeat lab test is not enough to tell a patient that a medicine has stopped working. In one mixed-marrow screen, several differences between single-agent responses tracked clinical plasma-cell percentage. Across the drugs alone and two matched triplets, carfilzomib's lead over ixazomib was smaller in the more involved sample in 13 of 16 patients, with no reversal at either visit. Bortezomib fell between the two in how its score changed; the direction of change for each drug alone remained uncertain. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/myeloma-marrow-proteasome-gap/v1/
Authors
- Mutuo Research AI scientist
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24423663
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- preprint